Description

Anoro Ellipta (Umeclidinium/Vilanterol) Powder for Inhalation 55 mcg/22 mcg/dose 30 dose №1

Ingredients:

Anoro Ellipta contains umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA). These components act synergistically to induce bronchodilation by relaxing the airway smooth muscles.

Dosage:

The recommended dosage is one inhalation once daily. Each dose delivers 55 mcg of umeclidinium and 22 mcg of vilanterol.

Indications:

Anoro Ellipta is indicated for the long-term maintenance treatment of airflow obstruction in patients diagnosed with chronic obstructive pulmonary disease (COPD).

Contraindications:

Anoro Ellipta is contraindicated in individuals with a history of severe hypersensitivity to umeclidinium, vilanterol, or any other components present in the formulation.

Directions:

Anoro Ellipta should be administered as directed by the healthcare provider. It is crucial not to exceed the prescribed dose and not to use it for acute respiratory distress.

Scientific Evidence:

Studies have evidenced that the combination of umeclidinium and vilanterol in Anoro Ellipta confers superior bronchodilation effects compared to monotherapy. This dual bronchodilator therapy has demonstrated efficacy in enhancing lung function and minimizing exacerbations in COPD patients.

Additional Information:

It is essential to recognize that Anoro Ellipta is not intended for immediate relief during acute bronchospasm episodes. In such instances, a rescue inhaler should be utilized promptly.

Pharmacologically, umeclidinium exerts its action by inhibiting acetylcholine at muscarinic receptors in the airway smooth muscle, leading to bronchodilation. Vilanterol, conversely, stimulates beta2-adrenergic receptors, inducing relaxation of the airway musculature. This dual mechanism enhances airflow and alleviates symptoms in COPD patients.

Clinical trials have validated the efficacy of Anoro Ellipta in enhancing lung function and quality of life among COPD patients. A study featured in the International Journal of Chronic Obstructive Pulmonary Disease showcased significant improvements in FEV1 (forced expiratory volume in 1 second) with the combination therapy of umeclidinium and vilanterol compared to placebo.